trending Market Intelligence /marketintelligence/en/news-insights/trending/rTUH3ioJwdyYU8x25mMiZQ2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Heron's pain drug helps patients avoid opioids after surgery in follow-up study

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Heron's pain drug helps patients avoid opioids after surgery in follow-up study

A study combining Heron Therapeutics Inc.'s non-opioid pain medication HTX-011 with common over-the-counter painkillers helped patients avoid opioids after undergoing foot surgery.

The San Diego-based biotechnology company examined HTX-011 in combination with acetaminophen and ibuprofen, compared to HTX-011-only, bupivacaine solution and placebo in patients undergoing bunionectomy surgery. In bunionectomy, an enlargement of bone and soft tissue at the base of the big toe is removed. The study is a follow up to a phase 3 clinical trial that similarly examined the drug's success in avoiding opioid use after bunionectomy with a different group of comparative treatments.

Heron noted that 77% of the patients who received HTX-011 with over-the-counter painkillers did not require opioids to manage their postoperative pain for 72 hours. Whereas 29%, 11% and 2% of the patients in the HTX-011-only, bupivacaine solution and placebo arms did not require opioids, respectively. The patients receiving the over-the-counter combination remained opioid-free through 28 days after surgery.

The company said the results from the follow-up study support the outcomes from a previous study in which 90% of hernia repair patients were opioid-free 72 hours after the surgery and 81% did not require opioids 28 days post-surgery.

The U.S. Food and Drug Administration granted a priority review to Heron's application for HTX-011 and will make a decision on the medicine by April 30.